Bao Pharma Executes HKD 3.00 Million Share Buyback, Bringing Treasury Shares to 0.38% of Mandate Capacity

Bulletin Express07-09

Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed a repurchase of 153,200 H-shares on 9 July 2026, executed on the Hong Kong Stock Exchange.

The transaction was completed at prices ranging from HKD 19.07 to HKD 19.87 per share, with a volume-weighted average repurchase price of HKD 19.53. Total consideration amounted to HKD 2.99 million.

Following the buyback, the company’s issued share capital (excluding treasury shares) fell by 0.10% to 153.74 million shares. Treasury shares on hand increased to 583,400, while total issued shares remained unchanged at 154.33 million.

The purchase forms part of the mandate approved on 26 May 2026, which authorises repurchases of up to 15.43 million shares. Cumulative buybacks under this mandate now stand at 583,400 shares, representing 0.38% of the authorised limit and 0.38% of issued shares on the mandate date.

Under Hong Kong listing rules, Bao Pharma is subject to a moratorium on new share issues or treasury-share sales until 8 August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111716596?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111716596","market":"hk","top_or_hot":-1,"title":"Bao Pharma Executes HKD 3.00 Million Share Buyback, Bringing Treasury Shares to 0.38% of Mandate Capacity","media":"Bulletin Express","content":"<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed a repurchase of 153,200 H-shares on 9 July 2026, executed on the Hong Kong Stock Exchange.</p>\n<p>The transaction was completed at prices ranging from HKD 19.07 to HKD 19.87 per share, with a volume-weighted average repurchase price of HKD 19.53. Total consideration amounted to HKD 2.99 million.</p>\n<p>Following the buyback, the company’s issued share capital (excluding treasury shares) fell by 0.10% to 153.74 million shares. Treasury shares on hand increased to 583,400, while total issued shares remained unchanged at 154.33 million.</p>\n<p>The purchase forms part of the mandate approved on 26 May 2026, which authorises repurchases of up to 15.43 million shares. Cumulative buybacks under this mandate now stand at 583,400 shares, representing 0.38% of the authorised limit and 0.38% of issued shares on the mandate date.</p>\n<p>Under Hong Kong listing rules, Bao Pharma is subject to a moratorium on new share issues or treasury-share sales until 8 August 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bao Pharma Executes HKD 3.00 Million Share Buyback, Bringing Treasury Shares to 0.38% of Mandate Capacity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBao Pharma Executes HKD 3.00 Million Share Buyback, Bringing Treasury Shares to 0.38% of Mandate Capacity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-09 19:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed a repurchase of 153,200 H-shares on 9 July 2026, executed on the Hong Kong Stock Exchange.</p>\n<p>The transaction was completed at prices ranging from HKD 19.07 to HKD 19.87 per share, with a volume-weighted average repurchase price of HKD 19.53. Total consideration amounted to HKD 2.99 million.</p>\n<p>Following the buyback, the company’s issued share capital (excluding treasury shares) fell by 0.10% to 153.74 million shares. Treasury shares on hand increased to 583,400, while total issued shares remained unchanged at 154.33 million.</p>\n<p>The purchase forms part of the mandate approved on 26 May 2026, which authorises repurchases of up to 15.43 million shares. Cumulative buybacks under this mandate now stand at 583,400 shares, representing 0.38% of the authorised limit and 0.38% of issued shares on the mandate date.</p>\n<p>Under Hong Kong listing rules, Bao Pharma is subject to a moratorium on new share issues or treasury-share sales until 8 August 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1111716596","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111716596","pubTimestamp":1783595182,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed a repurchase of 153,200 H-shares on 9 July 2026, executed on the Hong Kong Stock Exchange. The transaction was completed at prices...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"宝药业执行300万港元股票回购，库存股达到授权容量的0.38%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed a repurchase of 153,200 H-shares on 9 July 2026, executed on the Hong Kong Stock Exchange.\nThe transaction was completed at prices ranging from HKD 19.07 to HKD 19.87 per share, with a volume-weighted average repurchase price of HKD 19.53. Total consideration amounted to HKD 2.99 million.\nFollowing the buyback, the company’s issued share capital (excluding treasury shares) fell by 0.10% to 153.74 million shares. Treasury shares on hand increased to 583,400, while total issued shares remained unchanged at 154.33 million.\nThe purchase forms part of the mandate approved on 26 May 2026, which authorises repurchases of up to 15.43 million shares. Cumulative buybacks under this mandate now stand at 583,400 shares, representing 0.38% of the authorised limit and 0.38% of issued shares on the mandate date.\nUnder Hong Kong listing rules, Bao Pharma is subject to a moratorium on new share issues or treasury-share sales until 8 August 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111716596","isCrawlerRequest":true}